Found vs Hims & Hers
Two GLP-1 desks, one scoreboard. We put Found and Hims & Hers head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
The verdict
Found takes this head-to-head.
Found scores 88 to 85 on our six-factor Brief Score — A coaching-first program with the lowest identical price on both molecules — if you want the coaching lock-in that comes with it.
That doesn't make Hims & Hers a bad call — it's best for readers who want a familiar, app-driven consumer brand and nationwide access. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Found | Hims & Hers | |
|---|---|---|
| Brief Score | 88/100 (B+) | 85/100 (B) |
| Semaglutide | $129/mo | $199/mo |
| Tirzepatide | $129/mo | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Risingprice rising |
Found: Lowest identical-price line on the board — but bundled into a coaching subscription.
Hims & Hers: App-first reach is nationwide, but compounded supply has drawn industry-wide scrutiny.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.